151 related articles for article (PubMed ID: 20385901)
1. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
Phillips JT
Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
[No Abstract] [Full Text] [Related]
2. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
[TBL] [Abstract][Full Text] [Related]
3. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
4. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
5. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Sorensen PS; Bertolotto A
Neurology; 2007 Oct; 69(15):1552; author reply 1553. PubMed ID: 17923618
[No Abstract] [Full Text] [Related]
6. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Polman CH; Deisenhammer F; Giovannoni G; Killestein J; Schellekens H
Neurology; 2007 Oct; 69(15):1553-4; author reply 1555. PubMed ID: 17923619
[No Abstract] [Full Text] [Related]
7. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?
Giovannoni G; Goodman A
Neurology; 2005 Jul; 65(1):6-8. PubMed ID: 16009876
[No Abstract] [Full Text] [Related]
8. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
9. Treatment of multiple sclerosis with interferon beta 1b.
Dhib-Jalbut S; McFarland HF
Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
[TBL] [Abstract][Full Text] [Related]
10. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
[TBL] [Abstract][Full Text] [Related]
11. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Pachner AR
Neurology; 2007 Oct; 69(15):1555; author reply 1565. PubMed ID: 17923620
[No Abstract] [Full Text] [Related]
12. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
[TBL] [Abstract][Full Text] [Related]
13. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Giacomini PS; Arnold DL; Bar-Or A; Antel JP
Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
[No Abstract] [Full Text] [Related]
14. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
Farrell R; Bendtzen K; Bertolotto A; Clark B; Comabella M; Deisenhammer F; Fogdell-Hahn A; Giovannoni G; Hartung HP; Hemmer B; Hillert J; Kappos L; Killestein J; Lindberg R; Montalban X; Polman C; Sorensen PS;
J Int Med Res; 2008; 36(1):204-8; author reply 208-10. PubMed ID: 18230281
[No Abstract] [Full Text] [Related]
15. Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals.
Nazarov VD; Lapin SV; Mazing AV; Evdoshenko EP; Totolian AA
Biochemistry (Mosc); 2016 Nov; 81(11):1396-1400. PubMed ID: 27914464
[TBL] [Abstract][Full Text] [Related]
16. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Markovic-Plese S; Jewells V; Speer D
Neurology; 2009 Jun; 72(22):1965; author reply 1965-6. PubMed ID: 19487658
[No Abstract] [Full Text] [Related]
17. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
Hoffmann LA; Krumbholz M; Faber H; Kuempfel T; Starck M; Pöllmann W; Meinl E; Hohlfeld R
Neurology; 2007 Mar; 68(12):958-9. PubMed ID: 17372138
[No Abstract] [Full Text] [Related]
18. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
Sorensen PS; Tscherning T; Mathiesen HK; Langkilde AR; Ross C; Ravnborg M; Bendtzen K
Neurology; 2006 Nov; 67(9):1681-3. PubMed ID: 17101906
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab.
Sørensen PS; Koch-Henriksen N; Jensen PE
Neurology; 2011 Feb; 76(8):759-60. PubMed ID: 21339504
[No Abstract] [Full Text] [Related]
[Next] [New Search]
